Bulletin
Investor Alert

New York Markets After Hours

Market Pulse Archives

Oct. 26, 2020, 10:50 a.m. EDT

GeoVax shares rise on NIH vaccine deal

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    GeoVax Labs Inc. (GOVX)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

Shares of GeoVax Labs Inc. /zigman2/quotes/201030260/composite GOVX -0.13% were up 12.8% in trading on Monday after the company announced a patent and material licensing deal with the National Institutes of Health for COVID-19 vaccine development. As part of the agreement, the clinical-stage company said it will get access to patent rights in the virus' spike protein and has non-exclusive rights to develop a COVID-19 vaccine. No financial terms were disclosed. GeoVax said it has four COVID-19 vaccine candidates in development, though none have moved past preclinical studies into phased testing in humans. GeoVax's stock has tumbled 70.3% so far this year, compared with the S&P 500 /zigman2/quotes/210599714/realtime SPX +0.56% is up 7.2%.

/zigman2/quotes/201030260/composite
US : U.S.: Nasdaq
$ 2.73
-0.0036 -0.13%
Volume: 186,844
Nov. 23, 2020 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$10.42 million
Rev. per Employee
$195,983
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
3,577.59
+20.05 +0.56%
Volume: 2.51B
Nov. 23, 2020 5:02p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.